Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by imatinib in chronic myeloid leukemia

Leuk Lymphoma. 2017 Feb;58(2):473-474. doi: 10.1080/10428194.2016.1201575. Epub 2016 Jul 7.

Authors

Orlane Vatel¹, Cedric Aumont^{1

2}, Vincent Mathy¹, Morgane Petit¹, Joffrey Feriel^{1

2}, Ivan Sloma^{1

2}, Annelise Bennaceur-Griscelli^{1

2}, Ali G Turhan^{1

2}

Affiliations

¹ a Department of Hematology , Centre Hospitalier Universitaire, Université Paris Sud 11 , Le Kremlin Bicêtre , France.
² b INSERM U935 , Villejuif , France.

PMID: 27389710
DOI: 10.1080/10428194.2016.1201575

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
Blood Cell Count
Drug Hypersensitivity Syndrome / diagnosis*
Drug Hypersensitivity Syndrome / etiology*
Drug Substitution
Fusion Proteins, bcr-abl / genetics
Humans
Imatinib Mesylate / adverse effects*
Imatinib Mesylate / therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
Male
Middle Aged
Protein Kinase Inhibitors / adverse effects*
Protein Kinase Inhibitors / therapeutic use
Skin / pathology
Treatment Outcome

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
Imatinib Mesylate
Fusion Proteins, bcr-abl